Actavis | featured news

Exclusive: Watson close to $7 billion Actavis drug deal: sources

Watson Acquires Actavis

Watson Pharmaceuticals Inc is close to buying Swiss-based Actavis for around $7 billion, marking the latest deal between generics companies racing to achieve economies of scale, three sources familiar with the matter said.

 

Subscribe to this RSS topic: Syndicate content